146 results on '"Boran N"'
Search Results
2. 1120 An unsual presentation of a gynecological tumor: extragonadal yolk sac tumor of the vulva
- Author
-
Duru Çöteli, SA, primary, Yeter, G, additional, Usubütün, A, additional, and Boran, N, additional
- Published
- 2021
- Full Text
- View/download PDF
3. Gynecologic oncology
- Author
-
Oskav-Özcelik G., Hindenburg H. J., Klare P., Könsgen D., Mustea A., Heinrich G., Camara O., Lichtenegger W., Sehouli J., Tutuncu L., Ergur A. R., Gul I., Ertekin A., Yergok Y. Z., Ornek T., Tulunay G., Fetiel A., Tan O., Kose F., Haberal A., Noftolin F., Yermez E., Ata N., Sanci M., Sekü I., Karanfil C., Ispahi C., Akar M. E., Simsek T., Tamburaci E., Erdogan G., Pestereli E., Ingec M., Kadanali S., Erdogan F., Naki M. M., Tekcan C., Ergüler Y. S., Uysal A., Songülalp S., Kanadikirik F., Gezginc K., Görkemli H., Celik C., Acar A., Colakoglu M. C., Capar M., Akyürek C., Özbay K., Yardim T., Kurt S., Pilanci B., Tinar S., Camuzcuoglu H., Dicle N., Hanhan M., Inal M., Öztekin D., Dicle N., Özsaran Z., Tinar S., Demir B., Demir S., Gul T., Erden A. C., Bozaci E. A., Atabekoglu C., Taskin S., Sertcelik A., Ünlü C., Ortac F., Taskin S., Cengiz B., Bozaci E. A., Seval M., Ortac F., Taskin S., Yarci A., Kahraman K., Özmen B., Güngör M., Taskin S., Kahraman K., Özmen B., Yarci A., Güngör M., Taskin S., Bozaci E. A., Yarci A., Atabekoglu C., Ortac F., Hascalik S., Celik O., Ustun Y., Erdem G., Karadag N., Alkan A., Karakas H. M., Usta U., Mizrak B., Güzin K., Tekcan C., Naki M. M., Kayatas Eser S., Zemheri E., Kanadikirik F., Kurt S., Öztekin D., Karalti O., Inal M., Özsaran Z., Dicle N., Gunaydin G., Onan A., Taskiran C., Turp A., Yilmaz E., Kurdoglu M., Bozdayi G., Himmetoglu O., Kurdoglu Z., Gultekin M., Dursun P., Celik N. Y., Boynukalin K., Yuce K., Ayhan A., Dursun P., Gultekin M., Celik N. Y., Velipasaoglu M., Yuce K., Ayhan A., Gultekin M., Dursun P., Bozdag G., Celik N. Y., Guler Z., Yuce K., Ayhan A., Erkan L., Soylu F., Oztekin O., Tatli O., Eraslan T., Uysal D., Yavuzcan A., Yensel U., Baloglu A., Yildiz A., Köksal A., Tatli Ö., Tatli O., Ivit H., Yetimalar H., Cukurova K., Simsek E., Haydardedeoglu B., Asian E., Bulgan Kilicdag E., Erkanli S., Ozyurtseven Tarim E., Güzin K., Kayatas S., Tekcan C., Zemheri E., Kayabasoglu F., Kanadikirik F., Özmen B., Taskin S., Ünlü C., Ortac F., Uysal D., Aydin C., Yavuzcan A., Baloglu A., Salman M. C., Otegen U., Ozyuncu O., Bozdag G., Ayhan A., Salman M. C., Guven S., Ozyuncu O., Bozdag G., Usubutun A., Ayhan A., Oztekin D., Kurt S., Tinar S., Mit T., Balsak D., Hanhan M., Kurt S., Oztekin D., Tinar S., Karalti O., Inal M., Seyhan S., Turan T., Altinbas S., Boran N., Ozgul N., Ozer S., Ozfuttu A., Kose M. F., Boran N., Hizli D., Turan T., Halici F., Koc S., Bulbul D., Köse M. F., Vural M., Barut A., Tanriverdi H. A., Tutuncu L., Ergur A. R., Sancaktar M., Ertekin A., Yergok Y. Z., Iyibozkurt A. C., Topuz S., Bengisu E., Ilhan R., Berkman S., Boran N., Sarici S., Kose M. F., Tulunay G., Koc S., Ocalan R., Cavusoglu D., Haberal A., Boran N., Karacay Ö., Öztürkoglu E., Turan T., Cil A., Otken O. F., Köse M. F., Turan T., Öztürk F., Karacay Ö., Boran N., Özgül N., Tulunay G., Erdogan Z., Köse M. F., Koc S., Otken H., Yüksel K., Özdal B., Güngör T., Taner D., Tarhan I., Reyhan H., Aydogdu T., Mollamahmutoglu L., Daylan B. H., Zergeroglu S., Tunc I., Kahraman N., Gungor T., Bilge U., Güngör T., Yüksel K., Reyhan H., Aytan H., Tug M. T., Aydogdu T., Özdal B., Güngör T., Tug M., Cavkaytar S., Güngör T., Aydogdu T., Özdal B., Reyhan H., Daylan H. B., Tune I., Koc Ö., Gözübüyük S., Seckin S., Özdemir T., Abali R., Bozkurt S., Arikan I., Arikan D., Sahin A., Erdener O., Tülay Ö., Ergin S., Midilli K., Tan O., Kose F., Fatial A., Ornek T., Luk J., Tulunay G., Haberal A., Neftolin F., Aslan E., Kilicdag E., Bolat F., Erkanli S., Bal N., Kuscu E., Simsek E., Ayar A., Güzel Y., Vural M., Yetimalar M. H., Zeteroglu U., Köksal A., Soylu F., and Zeteroglu S.
- Published
- 2005
- Full Text
- View/download PDF
4. An investigation of IRMOF-16 as a pH-responsive drug delivery carrier of curcumin
- Author
-
Mengru Cai, Boran Ni, Xueling Hu, Kaixin Wang, Dongge Yin, Gongsen Chen, Tingting Fu, Rongyue Zhu, Xiaoxv Dong, Changhai Qu, and Xingbin Yin
- Subjects
Metal-organic frameworks ,Drug delivery ,Curcumin ,pH-responsive release ,Materials of engineering and construction. Mechanics of materials ,TA401-492 - Abstract
Metal–organic frameworks (MOFs) with tunable structures, high porosity, and abundant active sites are considered to be promising drug delivery systems (DDSs). In this study, novel MOFs-based nanoparticles (CUR@IRMOF-16) were successfully prepared using Zn-based IRMOF-16 as a carrier and curcumin (CUR) as the model drug. This nanocargo delivery platform has dual capabilities, enabling simultaneous drug delivery and fluorescence imaging. In vitro release experiments showed that nanoparticles were released more quickly under mildly acidic conditions, which proved their potential for tumor microenvironment-responsive drug release. Through in vitro cell experiments, it was found that the nano-drug platform had high antitumor cytotoxicity, which may be related to the mechanism of increasing intracellular reactive oxygen species (ROS), reducing intracellular mitochondrial membrane potential (MMP), and inducing apoptosis. In addition, confocal laser microscopy showed that CUR@IRMOF-16 could localize to the nucleus to exert an antitumor effect. Meanwhile, CUR@IRMOF-16 exhibited superior antitumor activity compared with pure CUR in vitro experiments. The biocompatibility test of IRMOF-16 showed reasonable biosafety, and no evidence of obvious toxicity was observed in vitro. CUR@IRMOF-16 has unique advantages with regard to pH response, biocompatibility, and antitumor efficacy, indicating that the nano-drug platform is a promising drug delivery carrier with an antitumor effect.
- Published
- 2022
- Full Text
- View/download PDF
5. Formation of a carbapenemase resistance detection algorithm for use in the routine laboratory
- Author
-
Boran, N., primary, Vivian, B., additional, Logan, C., additional, and Grogan, J., additional
- Published
- 2015
- Full Text
- View/download PDF
6. Undifferentiated uterine carcinoma: Analysis of eighteen cases
- Author
-
Üreyen, I., primary, Ilgin, H., additional, Turan, T., additional, Taşçi, T., additional, Karalök, A., additional, Boran, N., additional, Özfuttu, A., additional, and Tulunay, G., additional
- Published
- 2014
- Full Text
- View/download PDF
7. Undifferentiated uterine carcinoma: analysis of eighteen cases.
- Author
-
Üreyen, I, Ilgin, H, Turan, T, Tasçi, T, Karalök, A, Boran, N, Özfuttu, A, Tulunay, G, and Taşçi, T
- Abstract
Analysis of the surgicopathological characteristics and clinical follow-up of patients with undifferentiated uterine carcinoma (UUC) was conducted. A total of 18 cases operated between January 1993 and December 2013 were included. Among 1,690 patients with endometrial cancer, 18 patients (1.1%) had UUC. Lymph node involvement was detected in 70.6%; depth of myometrial invasion was ≥ 0.5 in 55.6%; lymphovascular space invasion was detected in 99.3%; cervical stromal invasion was positive in 27.8%; omental and adnexal involvement were detected in 11.8% and 38.9%, respectively. The median follow-up time of the 12 patients evaluated in the survival analysis was 66 months. In the follow-up period, recurrence or progression during adjuvant therapy were observed in four patients (33.3%) and two patients (16.6%) died of the disease. UUC manifests as an aggressive tumour. In conclusion, a high rate of survival could be achieved with complete staging surgery, including an extensive lymphadenectomy with the contribution of adjuvant therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia
- Author
-
TURAN, T., primary, KARACAY, O., additional, TULUNAY, G., additional, BORAN, N., additional, KOC, S., additional, BOZOK, S., additional, and KOSE, M.F., additional
- Published
- 2006
- Full Text
- View/download PDF
9. Comparison of single-breath vital capacity rapid inhalation with sevoflurane 5% and propofol induction on QT interval and haemodynamics for laparoscopic surgery
- Author
-
Sen, S., primary, Ozmert, G., additional, Boran, N., additional, Turan, H., additional, and Caliskan, E., additional
- Published
- 2004
- Full Text
- View/download PDF
10. Chylous ascites following para-aortic lymphadenectomy: a case report
- Author
-
BORAN, N, primary, CIL, A, additional, TULUNAY, G, additional, OZGUL, N, additional, and KOSE, M, additional
- Published
- 2004
- Full Text
- View/download PDF
11. Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways
- Author
-
Wenping Wang, XiaoXv Dong, Yi Liu, Boran Ni, Na Sai, Longtai You, Mingyi Sun, Yu Yao, Changhai Qu, Xingbin Yin, and Jian Ni
- Subjects
Itraconazole ,HepG2 cells ,PI3K/AKT/mTOR pathway ,Wnt/β-catenin pathway ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers with the highest morbidity and mortality. It is necessary to develop new anti-liver cancer drugs. Itraconazole is a popular systemic anti-fungal drug with a strong anti-tumor effect. However, so far, it is not clear whether itraconazole has specific anti-tumor effect on liver cancer. The purpose of this study was to investigate itraconazole resistant effect of liver cancer and to explore its potential anti-cancer mechanism. The effect of itraconazole on the proliferation of liver cancer cells was studied with MTT assay. Flow cytometry was used to determine the effect of itraconazole on apoptosis, cell cycle distribution, changes in intracellular reactive oxygen species (ROS) and mitochondrial membrane potential (MMP). In addition, after DAPI staining, nuclear morphological changes were observed under the fluorescent microscope, and the release of lactate dehydrogenase (LDH) was measured using the microplate reader. Finally, the expressions of proteins related to the anti-tumor signaling pathway were determined by Western blotting. The results showed that itraconazole significantly inhibited the proliferation of HepG2 and Bel-7405 cells. In addition, the data showed that itraconazole induced apoptosis in HepG2 cells, increased the production of ROS, blocked cell cycle, and decreased MMP. Furthermore, itraconazole inhibited HCC cell growth and promoted apoptosis through the Hh, Wnt/catenin, AKT/mTOR/S6K, ROS and death receptor pathways. Finally, we come to the conclusion that itraconazole exerts anti-liver cancer effect, and has potential for use as a new drug for liver cancer in clinic.
- Published
- 2020
- Full Text
- View/download PDF
12. Primary choriocarcinoma of the uterine cervix in a postmenopausal patient: a case report
- Author
-
Baykal, C, primary, Tulunay, G, additional, Bülbül, D, additional, Boran, N, additional, and Köse, M.F, additional
- Published
- 2003
- Full Text
- View/download PDF
13. PREGNANCY OUTCOMES AND MENSTRUEL FUNCTION AFTER FERTILITY SPARING SURGERY FOR PURE OVARIAN DYSGERMINOMAS
- Author
-
Boran, N., primary, Tulunay, G., additional, Caliskan, E., additional, Kose, M. F., additional, and Haberal, A., additional
- Published
- 2003
- Full Text
- View/download PDF
14. EXTRAPERITONEAL LYMPH NODE DISSECTION (EPLND) IN LOCALLY ADVANCED CERVICAL CANCER; PRELIMINARY RESULTS FROM A TURKISH INSTITUTION
- Author
-
Kose, M. F., primary, Boran, N., additional, Baykal, C., additional, Ozturk, N., additional, Ozgul, N., additional, Tulunay, G., additional, Ocalan, R., additional, Koc, S., additional, and Haberal, A., additional
- Published
- 2003
- Full Text
- View/download PDF
15. ACCURACY OF PREOPERATIVE MR IMAGING IN STAGING OF CERVICAL CARCINOMA
- Author
-
Hazirolan, T., primary, Kayikcioglu, F., additional, Tulunay, G., additional, Ozgul, N., additional, Boran, N., additional, Kose, M. F., additional, Akata, D., additional, and Haberal, A., additional
- Published
- 2003
- Full Text
- View/download PDF
16. SENTINEL LYMPH NODE DISSECTION IN EARLY STAGE VULVAR CANCER: A PRELIMINARY STUDY
- Author
-
Boran, N., primary, Kayikcioglu, F., additional, Baykal, C., additional, Kose, M. F., additional, Kapucuoglu, N., additional, Demirer, A. A., additional, and Kir, M., additional
- Published
- 2003
- Full Text
- View/download PDF
17. COMPARISON OF HGF (HEPATOCYTE GROWTH FACTOR) LEVELS OF EPITHELIAL OVARIAN CANCER CYST FLUIDS WITH BENIGN OVARIAN CYSTS
- Author
-
Baykal, C., primary, Demirtas, E., additional, Al, A., additional, Ayhan, A., additional, Demirol, A., additional, Yuce, K., additional, Boran, N., additional, Tulunay, G., additional, and Kose, F., additional
- Published
- 2003
- Full Text
- View/download PDF
18. NEOADJUVANT CHEMOTHERAPY IN STAGE IB2 CARCINOMA OF THE CERVIX
- Author
-
Tulunay, G., primary, Koc, S., additional, Ozgul, N., additional, Boran, N., additional, Baykal, C., additional, Ocalan, R., additional, Kog, I., additional, and Kose, M. F., additional
- Published
- 2003
- Full Text
- View/download PDF
19. UTERINE CARCINOSARCOMAS: COMPARISON OF SURVIVAL IN EARLY AND ADVANCED STAGES
- Author
-
Ozgul, N., primary, Tulunay, G., additional, Baykal, C., additional, Boran, N., additional, Ocalan, R., additional, Kose, M. F., additional, and Ozfuttu, A., additional
- Published
- 2003
- Full Text
- View/download PDF
20. AMIFOSTINE HAS NO PROTECTIVE EFFECT DURING CONCOMITTANT CHEMORADIOTHERAPY GIVEN FOR CERVICAL CARCINOMA
- Author
-
Tulunay, G., primary, Gultekin, B., additional, Boran, N., additional, Ozgul, N., additional, Baykal, C., additional, Ozyar, E., additional, Atahan, L., additional, Senyuva, M., additional, and Kose, M. F., additional
- Published
- 2003
- Full Text
- View/download PDF
21. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma
- Author
-
Lu, F. Kayikciog, primary, Kose, M. F., additional, Boran, N., additional, Caliskan, E., additional, and Tulunay, G., additional
- Published
- 2001
- Full Text
- View/download PDF
22. Significance of Serum and Peritoneal Fluid Lactate Dehydrogenase Levels in Ovarian Cancer
- Author
-
Boran, N., primary, Kayikcioglu, F., additional, Yalvaç, S., additional, Tulunay, G., additional, Ekinci, U., additional, and Köse, M.F., additional
- Published
- 2000
- Full Text
- View/download PDF
23. What is the impact of cervical invasion on lymph node metastasis in patients with stage IIIC endometrial cancer?
- Author
-
Turan T, Hizli D, Yilmaz SS, Gundogdu B, Boran N, Tulunay G, Ozfuttu A, and Faruk Kose M
- Published
- 2012
24. Experience in stage IB2 cervical cancer and review of treatment.
- Author
-
Turan T, Yildirim BA, Tulunay G, Boran N, Yildiz F, and Köse MF
- Abstract
Background: The aim of the study is to evaluate and compare the efficacy of neoadjuvant chemotherapy (NACT), radical hysterectomy (RH) and radiotherapy (RT) in the treatment of stage IB2 cervical cancer. Methods: Medical records of 86 patients with stage IB2 cervical cancer between 1993 and 2006 were evaluated. Patients who underwent type III RH ± bilateral salphingo-oophorectomy and para-aortic and pelvic lymphadenectomy constituted the RH group (n=18). Patients who were treated with constituted the RT group (n=20). Patients who underwent any of the combination chemotherapies (cisplatin/5-fluorouracyl, cisplatin/UFT® or paclitaxel/carboplatin) followed by RH or RT constituted the NACT group (n=36). Results: Seventy-four patients were included in the study. The median follow-up was 48.5 months and the mean tumor size was 51.4mm. The groups were similar in terms of follow-up duration and tumor size. However mean age of the patients was higher in the RT group and nonsquamous type cervical cancer was more frequent in the RH group. Disease free survival (DFS) and overall survival (OS) were 75.7%. DFS rate was 65% in the RT group, 77.8% in the RH group and 80.6% in the NACT group. OS rates were 65%, 77.8% and 83.3% respectively. The groups were similar in terms of DFS and OS rates. Conclusion: In our study, none of the treatment modalities were shown to be superior in terms of efficacy. There is need for additional prospective studies comparing multimodal treatment regimens in stage IB2 cervical cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2010
25. Triptolide Induces Apoptosis Through Fas Death and Mitochondrial Pathways in HepaRG Cell Line
- Author
-
Longtai You, Xiaoxv Dong, Boran Ni, Jing Fu, Chunjing Yang, Xingbin Yin, Xin Leng, and Jian Ni
- Subjects
triptolide ,hepatotoxicity ,HepaRG cells ,ROS ,apoptosis ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Triptolide isolated from the traditional Chinese herb Tripterygium wilfordii Hook F., possesses anti-tumor, anti-fertility, and anti-inflammatory properties. Triptolide-induced hepatotoxicity has continued to engage the attention of researchers. However, not much is yet known about the cytotoxicity of triptolide, and the precise mechanisms involved. In the present study, we investigated the cytotoxicity of triptolide and its underlying mechanisms, using the in vitro model (HepaRG cell). The results demonstrated that triptolide significantly reduced cell viability and induced apoptosis in HepaRG cells in a dose- and time-dependent manner. Triptolide treatment also provoked reactive oxygen species (ROS) generation and depolarization of mitochondrial membrane potential (MMP). Moreover, triptolide dose-dependently increased the protein expression levels of Fas, Bax, p53, p21, cyclin E, cleaved caspase-3, 8, and 9; and subsequent cleavage of poly (ADP-ribose) polymerase (PARP). However, the protein expression of Bcl-2, cyclin A, and CDK 2 were significantly decreased. These results suggest that triptolide inhibits cell proliferation and induces apoptosis via the Fas death pathway and the mitochondrial pathway.
- Published
- 2018
- Full Text
- View/download PDF
26. Treatment results and prognostic factors in inoperable carcinoma of the cervix treated with external plus high dose brachytherapy
- Author
-
Garipagaoglu, M., Yalvac, S., Kose, F., Tulunay, G., Kayikcioglu, F., Cakmak, A., Haberal, A., Boran, N., Adli, M., and Hayran, M.
- Published
- 1999
- Full Text
- View/download PDF
27. Accuracy of frozen section diagnosis in borderline ovarian malignancy.
- Author
-
Kayikçioglu, F, Pata, O, Cengiz, S, Tulunay, G, Boran, N, Yalvaç, S, and Köse, M F
- Published
- 2000
28. Multicenter analysis of gestational trophoblastic neoplasia in Turkey
- Author
-
Ss, Ozalp, Telli E, Oge T, Gökhan Tulunay, Boran N, Turan T, Yenen M, Kurdoglu Z, Ozler A, Yuce K, Ulker V, Arvas M, Demirkiran F, Bese T, Tokgozoglu N, Onan A, Sanci M, Gokcu M, Tosun G, and Dikmen Y
29. Primary fallopian tube carcinoma: a retrospective multicenter study
- Author
-
Tulunay, G., Arvas, M., Demir, B., Fuat Demirkıran, Boran, N., Bese, T., Ozgul, N., Kose, M. F., and Kosebay, D.
- Subjects
Adult ,Turkey ,Fallopian Tube Neoplasms ,Humans ,Female ,Middle Aged ,Neoplasm Recurrence, Local ,Survival Analysis ,Medical Records ,Aged ,Neoplasm Staging ,Retrospective Studies - Abstract
This retrospective multicenter study aimed to assess the survival and prognostic factors of primary fallopian tube carcinoma.The medical records of 29 patients with fallopian tube carcinoma from two centers were reviewed for age, stage, surgical intervention, relapse and survival.The mean age of the patients was 56 years (range, 37-76). Six patients were in Stage I (20.7%), eight cases in Stage II (27.6%), nine cases in Stage III (31%) and two cases in Stage IV (6.9%). Data on stage was not available in four cases (13.8). Fifteen patients underwent lymph node evaluation. The median follow-up was 29 months (range, 3-122). The median survival was 95 months with a 5-year survival rate of 69.7%. The median progression-free survival was 76 months with a 5-year survival rate of 51.8%.Age, stage and lymphadenectomy were found to be significant prognostic factors on overall survival.
30. Ultra-radical surgery versus standard-radical surgery for the primary cytoreduction of advanced epithelial ovarian cancer; long-term tertiary center experiences.
- Author
-
Aksan A, Boran N, Sinem Duru Coteli A, and Ustun Y
- Abstract
Objective: To compare overall survival (OS) and morbidity outcomes in patients with advanced epithelial ovarian/tubal/peritoneal cancer undergoing standard-radical (SR) and ultra-radical (UR) surgical procedures based on NICE classification., Study Design: This retrospective study analyzed data from 282 patients with 2014 FIGO stage III-IV epithelial ovarian cancer operated on between January 2006 and January 2019. The study compared OS, progression-free survival (PFS), and morbidity between SR and UR surgeries. Parameters influencing OS, including preoperative, postoperative, and post-adjuvant chemotherapy CA-125 values, surgical procedures, post-surgical residual tumor, histopathological grade, and FIGO surgical stage, were assessed., Results: Out of 282 patients, 256 met the inclusion criteria. SR surgery was performed in 48 %, and UR surgery in 52 %. The mean preoperative CA-125 value was 1200 ± 1914.83, decreasing to 240.32 ± 373.87 postoperatively. The mean follow-up period was 63.01 ± 47.56 months. UR surgery correlated with significantly higher postoperative complications (p < 0.001), histopathological grade (p = 0.023), FIGO stage (p < 0.001), three-year death rates, and overall mortality rates (p = 0.035). FIGO stage and total metastatic lymph nodes emerged as independent prognostic factors for overall and PFS., Conclusion: In the treatment of epithelial ovarian cancer, evaluating the extent of the tumor before the surgery and showing maximal effort to minimize the residual tumor volume instead of applying UR procedures as the first choice seems to be the most important factor that can affect survival., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Does HPV-18 co-infection increase the risk of cervical pathology in individuals with HPV-16?
- Author
-
Gökkaya M, Alcı A, Aytekin O, Unsal M, Cakır C, Oktar O, Yalcin N, Kahraman A, Tokalioglu A, Ersak B, Yıldırım HEK, Koc S, Toptas T, Kilic F, Celik F, Boran N, Ustun Y, Tekin OM, Comert GK, Korkmaz V, Turan T, and Ureyen I
- Abstract
Objective: We aimed to investigate differences between HPV-16 mono- and HPV-16/18 co-infections in terms of cervical dysplasia and invasive cancer., Methods: This multicentre, retrospective study spanned from December 2017 to December 2020, involving women who visited gynaecological oncology clinics for colposcopy with either HPV-16 or HPV-16/18 positivity. A total of 736 patients, 670 in Group 1 (HPV-16 positivity) and 66 in Group 2 (HPV-16/18 positivity), were compared for the presence of CIN2+ lesions detected by colposcopic biopsy or endocervical curettage (ECC). Exclusions included hysterectomized patients, those with prior gynaecological cancers, and patients with HPV positivity other than types 16 and 18., Results: Among the included patients, 42.4% had a diagnosis of CIN2+ lesions. The cytology results demonstrated abnormal findings in 45.3% in Group 1 and 42.2% in Group 2, with no significant difference between the groups. ECC revealed CIN2+ lesion in 49 (8.7%) patients in group 1, while only 1 (1.7%) patient had CIN2+ lesion in group 2. There was no difference between 2 groups in terms of ECC result (p = 0.052). In group 1, 289 (43.1%) patients had CIN2+ lesion, while 23 (34.8%) patients had CIN2+ lesions in group 2. There was no difference between group 1 and 2 in terms of diagnosis of CIN2+ lesions (p = 0.19)., Conclusion: This multicentre retrospective study found no significant differences between HPV-16 mono- and HPV-16/18 co-infections regarding cervical pathologies. Larger studies are needed to validate and further explore these findings., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
32. Sensitivity of frozen section analysis in patients with ovarian adult granulosa cell tumor, a multi-center study.
- Author
-
Ureyen I, Toptas T, Tokalıoğlu A, Sahin M, Oktar O, Kole M, Alcı A, Ozturk C, Ozmen F, Akturk SE, Erdogan O, Ersak B, Kilic F, Bas S, Cakir C, Kocak O, Kilic Ç, Ucar G, Korkmaz V, Narin MA, Uncu D, Sanci M, Kimyon Comert G, Ozdal B, Tekin Moralıoglu O, Engin Ustun Y, Boran N, Taskin S, Tasci T, Ortac F, and Turan T
- Subjects
- Humans, Female, Adult, Middle Aged, Aged, Retrospective Studies, Adolescent, Young Adult, Aged, 80 and over, Ascites pathology, Granulosa Cell Tumor pathology, Granulosa Cell Tumor blood, Frozen Sections, Ovarian Neoplasms pathology, Ovarian Neoplasms blood, CA-125 Antigen blood, Sensitivity and Specificity
- Abstract
Introduction: We aimed to demonstrate the sensitivity of frozen section for patients with adult granulosa cell tumor (AGCT) and analyze the clinico-pathological factors that may be associated with sensitivity., Material Methods: This is a multicenter study including data of 10 Gynecological Oncology Departments. Frozen-section results of patients who had ovarian AGCT at the final pathology report were retrospectively analyzed. The relation between clinico-pathological characteristics such as age, tumor size, Ca-125 level, presence of ascites, omental metastasis, menopausal status and peritoneal cytology, and the sensitivity of frozen section in patients with AGCT were evaluated. The sensitivity of frozen section diagnosis was determined by comparing the frozen section result with the final pathological diagnosis., Results: Frozen section results of 274 patients with AGCT were obtained. The median age of the patients was 52 years (range, 17-82 years). Totally, 144 (52.7%, n = 273) patients were postmenopausal. The median tumour size was 90 mm (range, 9-700 mm). The median preoperative Ca-125 level was 23 IU/mL (range, 2-995 IU/mL). The sensitivity of frozen section for detecting AGCT was 76.3%. Any association between the sensitivity of frozen section and menopausal status, presence of ascites, positive cytology, omental metastasis, tumor size, Ca-125 level, age could not be shown., Conclusion: It is important to know the diagnosis of AGCT intraoperatively, and we demonstrated the sensitivity of frozen-section for these tumors as 76.3%., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
33. The role of neoadjuvant chemotherapy before radical surgery in stage IB2/IIA2 squamous cell cervical cancers.
- Author
-
Alci A, Aytekin O, Ersak B, Kilic F, Oktar O, Caner C, Korkmaz V, Comert GK, Selcuk İ, Toptas T, Boran N, Tasci T, Karalok A, Basaran D, Tekin OM, Ustun YE, Turan T, and Ureyen I
- Subjects
- Humans, Female, Middle Aged, Adult, Chemotherapy, Adjuvant methods, Chemotherapy, Adjuvant statistics & numerical data, Aged, Retrospective Studies, Disease-Free Survival, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms surgery, Uterine Cervical Neoplasms therapy, Uterine Cervical Neoplasms drug therapy, Neoadjuvant Therapy methods, Neoadjuvant Therapy statistics & numerical data, Carcinoma, Squamous Cell surgery, Carcinoma, Squamous Cell therapy, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell pathology, Hysterectomy methods, Hysterectomy statistics & numerical data, Neoplasm Staging
- Abstract
Background: This study aimed to evaluate the outcomes of patients diagnosed with stage IB2/IIA2 cervical squamous cell carcinoma who underwent neoadjuvant chemotherapy (NACT) prior to radical hysterectomy compared to those who did not receive NACT before surgery., Materials and Methods: This is a multicenter study including data of 6 gynecological oncology departments. The study is approved from one of the institution's local ethics committee. Patients were stratified into two cohorts based on the receipt of NACT preceding their surgical intervention. Clinico-pathological factors and progression-free survival were analyzed., Results: Totally 87 patients were included. Lymphovascular space invasion (LVSI) was observed as 40% in the group receiving NACT, while it was 66.1% in the group not receiving NACT (p = 0.036). Deep stromal invasion (> 50%) was 56% in the group receiving NACT and 84.8% in the group not receiving NACT (p = 0.001). In the univariate analysis, application of NACT is statistically significant among the factors that would be associated with disease-free survival. Consequently, a multivariate analysis was conducted for progression-free survival, incorporating factors such as the depth of stromal invasion, the presence of LVSI, and the administration of NACT. Of these, only the administration of NACT emerged as an independent predictor associated with decreased progression-free survival. (RR:5.88; 95% CI: 1.63-21.25; p = 0.07)., Conclusions: NACT shouldn't be used routinely in patients with stage IB2/IIA2 cervical cancer before radical surgery. Presented as oral presentation at National Congress of Gynaecological Oncology & National Congress of Cervical Pathologies and Colposcopy (2022/ TURKEY)., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
34. Do HPV 16 positive/ASC-H cervical cancer screening results predict CIN 2+ better than other high-risk HPV subtypes?
- Author
-
Tokalıoğlu AA, Alcı A, Oktar O, Ünsal M, Yalçın N, Aytekin O, Çelik F, Tiryaki Güner G, Ersak B, Kılıç F, Ayhan S, Akar İnan S, Çakır C, Yalçın H, Korkmaz V, Koç S, Boran N, Kimyon Cömert G, Toptaş T, Üreyen I, Türkmen O, Moraloğlu Tekin Ö, Erdoğan F, Engin-Üstün Y, and Turan T
- Abstract
Objective: To determine whether patients with atypical squamous cells, cannot exclude high grade squamous intraepithelial neoplasia (ASC-H) cytology have a correlation between high-risk human papillomavirus (HPV) type and CIN 2+
1 lesion in final pathology., Material and Methods: The study was conducted retrospectively, using data from three tertiary gynecologic oncology centers located in various regions of Turkey. Data from 5,271 patients who had colposcopy between January 2003 and January 2021 were analyzed., Results: A total of 163 patients who had ASC-H cervical cytology test results, based on the Bethesda 2014 classification were eligible, and of these 83 (50.9%) who tested positive for HPV were included in the study. There was no correlation between the occurrence of CIN 2+ lesions and age (p=0.053). If there was any HPV 16 positivity (only HPV 16, HPV 16 and 18, HPV 16 and others) the presence of CIN 2+ lesions in the final pathology increased significantly. In HPV 16 positive ASC-H patients, the probability of CIN 2+ lesions in the final pathology were 72.5% while this rate was 48.1% in HPV 16 negative group (p=0.033)., Conclusion: The guidelines do not provide a comprehensive definition of the role of the HPV test in managing ASC-H. Positive high-risk HPV types, especially HPV 16, together with an ASC-H smear result should bring to mind the possibility of high-grade dysplasia., Competing Interests: Conflict of Interest: No conflict of interest is declared by the authors., (Copyright© 2024 The Author. Published by Galenos Publishing House on behalf of Turkish-German Gynecological Association. This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License.)- Published
- 2024
- Full Text
- View/download PDF
35. Prognostic factors of adult granulosa cell tumors of the ovary: a Turkish retrospective multicenter study.
- Author
-
Oktar O, Korkmaz V, Tokalıoğlu A, Öztürk Ç, Erdoğan Ö, Uçar Y, Koca Yıldırım HE, Hanedan C, Kılıç F, Ersak B, Yalçın N, Özmen F, Kahraman A, Esen SA, Baş S, Özdaş ED, Selçuk İ, Uçar G, Koçak Ö, Çakır C, Koç S, Kılıç Ç, Cömert GK, Üreyen I, Toptaş T, Narin MA, Taşçı T, Taşkın S, Boran N, Sancı M, Köş FT, Tekin ÖM, Üstün YE, Ortaç F, and Turan T
- Subjects
- Humans, Female, Middle Aged, Adult, Retrospective Studies, Aged, Prognosis, Turkey epidemiology, Aged, 80 and over, Young Adult, Lymph Node Excision, Neoplasm Staging, Hysterectomy, Chemotherapy, Adjuvant, Lymphatic Metastasis, Granulosa Cell Tumor pathology, Granulosa Cell Tumor therapy, Granulosa Cell Tumor mortality, Ovarian Neoplasms pathology, Ovarian Neoplasms mortality, Ovarian Neoplasms therapy
- Abstract
Objective: To define the clinical, histopathological features and the prognostic factors affecting survival in patients with adult granulosa cell tumors of the ovary (AGCT)., Methods: A 322 patients whose final pathologic outcome was AGCT treated at nine tertiary oncology centers between 1988 and 2021 participated in the study., Results: The mean age of the patients was 51.3±11.8 years and ranged from 21 to 82 years. According to the International Federation of Gynecology and Obstetrics 2014, 250 (77.6%) patients were stage I, 24 (7.5%) patients were stage II, 20 (6.2%) patients were stage III, and 3 (7.8%) were stage IV. Lymphadenectomy was added to the surgical procedure in 210 (65.2%) patients. Lymph node involvement was noted in seven (3.3%) patients. Peritoneal cytology was positive in 19 (5.9%) patients, and 13 (4%) had metastases in the omentum. Of 285 patients who underwent hysterectomy, 19 (6.7%) had complex hyperplasia with atypia/endometrial intraepithelial neoplasia, and 8 (2.8%) had grade 1 endometrioid endometrial carcinoma. It was found that 93 (28.9%) patients in the study group received adjuvant treatment. Bleomycin, etoposide, cisplatin was the most commonly used chemotherapy protocol. The median follow-up time of the study group was 41 months (range, 1-276 months). It was noted that 34 (10.6%) patients relapsed during this period, and 9 (2.8%) patients died because of the disease. The entire cohort had a 5-year disease-free survival (DFS) of 86% and a 5-year disease-specific survival of 98%. Recurrences were observed only in the pelvis in 13 patients and the extra-abdominal region in 7 patients. The recurrence rate increased 6.168-fold in patients with positive peritoneal cytology (95% confidence interval [CI]=1.914-19.878; p=0.002), 3.755-fold in stage II-IV (95% CI=1.275-11.063; p=0.016), and 2.517-fold in postmenopausal women (95% CI=1.017-6.233; p=0.046) increased., Conclusion: In this study, lymph node involvement was detected in 3.3% of patients with AGCT. Therefore, it was concluded that lymphadenectomy can be avoided in primary surgical treatment. Positive peritoneal cytology, stage, and menopausal status were independent prognostic predictors of DFS., Competing Interests: No potential conflict of interest relevant to this article was reported., (© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
36. Defining the relationship between ovarian adult granulosa cell tumors and synchronous endometrial pathology: Does ovarian tumor size correlate with endometrial cancer?
- Author
-
Tokalioglu AA, Oktar O, Sahin M, Ozturk C, Erdogan O, Yildirim HEK, Ucar Y, Kilic F, Ersak B, Yalcin N, Ozmen F, Alci A, Bas S, Gorgulu G, Selcuk I, Ucar G, Kocak O, Cakir C, Kilic C, Comert GK, Ureyen I, Toptas T, Narin MA, Tasci T, Taskin S, Boran N, Ozdal B, Sanci M, Uncu D, Korkmaz V, Tekin OM, Ustun Y, Ortac F, and Turan T
- Subjects
- Adult, Humans, Female, Retrospective Studies, Granulosa Cell Tumor surgery, Endometrial Hyperplasia, Ovarian Neoplasms pathology, Endometrial Neoplasms pathology
- Abstract
Objective: The main feature of adult granulosa cell tumors (AGCT) is their capacity to secrete hormones, with nearly all of them capable of synthesizing oestradiol. The primary goal of this study is to identify synchronized endometrial pathologies, particularly endometrial cancer, in AGCT patients who had undergone a hysterectomy., Materials and Methods: The study cohort comprised retrospectively of 316 AGCT patients from 10 tertiary gynecological oncology centers. AGCT surgery consisted of bilateral salpingo-oophorectomy, hysterectomy, peritoneal cytology, omentectomy, and the excision of any suspicious lesion. The median tumor size value was used to define the relationship between tumor size and endometrial cancer. The relationship between each value and endometrial cancer was evaluated., Results: Endometrial intraepithelial neoplasia, or hyperplasia with complex atypia, was detected in 7.3% of patients, and endometrial cancer in 3.1% of patients. Age, menopausal status, tumor size, International Federation of Gynecology and Obstetrics stage, ascites, and CA-125 level were not statistically significant factors to predict endometrial cancer. There was no endometrial cancer under the age of 40, and 97.8% of women diagnosed with endometrial hyperplasia were over the age of 40. During the menopausal period, the endometrial cancer risk was 4.5%. Developing endometrial cancer increased to 12.1% from 3.2% when the size of the tumor was >150 mm in menopausal patients (p = 0.036)., Conclusion: Endometrial hyperplasia, or cancer, occurs in approximately 30% of AGCT patients. Patients diagnosed with AGCT, especially those older than 40 years, should be evaluated for endometrial pathologies. There may be a relationship between tumor size and endometrial cancer, especially in menopausal patients., (© 2024 Japan Society of Obstetrics and Gynecology.)
- Published
- 2024
- Full Text
- View/download PDF
37. Clinical features of gestational choriocarcinoma: A retrospective bicentric study.
- Author
-
Yuksel D, Aytekın O, Oktar O, Ayhan S, Ozkaya Ucar Y, Cakır C, Boran N, Korkmaz V, Koc S, Türkmen O, Kimyon Cömert G, Moraloğlu Tekin O, Engin Ustün Y, and Turan T
- Subjects
- Pregnancy, Female, Humans, Adult, Middle Aged, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Prognosis, Gestational Trophoblastic Disease drug therapy, Gestational Trophoblastic Disease pathology, Choriocarcinoma drug therapy
- Abstract
Objective: To investigate the clinicopathological features, prognostic factors, treatment, clinical response, and outcome of gestational choriocarcinoma (GCC)., Materials and Methods: A retrospective review was made of the clinicopathological and survival data of 13 patients who were diagnosed and treated for GCC in two referral centers in Turkey between 1992 and 2020., Results: The median age of patients was 36 years (range, 27-54 years), and seven were ≤39 years. The antecedent pregnancy was a term in nine (69.2%) cases, and the risk score was ≥7 in 11 (84.6%). According to the International Federation of Gynecology and Obstetrics 2009 staging, eight cases were in stage I, two in stage III, and three in stage IV. With the exception of one patient, all the others received combination chemotherapy (CT), and two of those were also treated with radiotherapy. Chemoresistance developed in 50% (6/12), and second-line CT was given to four of these. The overall complete response rate was 69.2%. Four patients died of chemoresistance and disease progression, all of them were with antecedent-term pregnancy, had high scores ≥7, and had metastases., Conclusion: GCC is a unique subtype of gestational trophoblastic neoplasia, which differs from others in terms of poor prognosis, a frequent tendency to early metastasis, and resistance to treatment. To be able to achieve the most efficient therapy and prognosis, histopathology-based risk models should be developed., (© 2023 John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
38. Potential value of a rapid syndromic multiplex PCR for the diagnosis of native and prosthetic joint infections: a real-world evidence study.
- Author
-
Pascual S, Noble B, Ahmad-Saeed N, Aldridge C, Ambretti S, Amit S, Annett R, O'Shea SA, Barbui AM, Barlow G, Barrett L, Berth M, Bondi A, Boran N, Boyd SE, Chaves C, Clauss M, Davies P, Dianzo-Delgado IT, Esteban J, Fuchs S, Friis-Hansen L, Goldenberger D, Golle A, Groonroos JO, Hoffmann I, Hoffmann T, Hughes H, Ivanova M, Jezek P, Jones G, Ceren Karahan Z, Lass-Flörl C, Laurent F, Leach L, Horsbøll Pedersen ML, Loiez C, Lynch M, Maloney RJ, Marsh M, Milburn O, Mitchell S, Moore LSP, Moffat L, Murdjeva M, Murphy ME, Nayar D, Nigrisoli G, O'Sullivan F, Öz B, Peach T, Petridou C, Prinz M, Rak M, Reidy N, Rossolini GM, Roux AL, Ruiz-Garbajosa P, Saeed K, Salar-Vidal L, Salas Venero C, Selvaratnam M, Senneville E, Starzengruber P, Talbot B, Taylor V, Trebše R, Wearmouth D, Willinger B, Wouthuyzen-Bakker M, Couturier B, and Allantaz F
- Abstract
Introduction : The BIOFIRE Joint Infection (JI) Panel is a diagnostic tool that uses multiplex-PCR testing to detect microorganisms in synovial fluid specimens from patients suspected of having septic arthritis (SA) on native joints or prosthetic joint infections (PJIs). Methods : A study was conducted across 34 clinical sites in 19 European and Middle Eastern countries from March 2021 to June 2022 to assess the effectiveness of the BIOFIRE JI Panel. Results : A total of 1527 samples were collected from patients suspected of SA or PJI, with an overall agreement of 88.4 % and 85 % respectively between the JI Panel and synovial fluid cultures (SFCs). The JI Panel detected more positive samples and microorganisms than SFC, with a notable difference on Staphylococcus aureus , Streptococcus species, Enterococcus faecalis , Kingella kingae , Neisseria gonorrhoeae , and anaerobic bacteria. The study found that the BIOFIRE JI Panel has a high utility in the real-world clinical setting for suspected SA and PJI, providing diagnostic results in approximately 1 h. The user experience was positive, implying a potential benefit of rapidity of results' turnover in optimising patient management strategies. Conclusion : The study suggests that the BIOFIRE JI Panel could potentially optimise patient management and antimicrobial therapy, thus highlighting its importance in the clinical setting., Competing Interests: At least one of the (co-)authors is a member of the editorial board of Journal of Bone and Joint Infection. The peer-review process was guided by an independent editor, and the authors also have no other competing interests to declare., (Copyright: © 2024 Stéphanie Pascual et al.)
- Published
- 2024
- Full Text
- View/download PDF
39. Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer.
- Author
-
Karacin C, Sunar V, Urakci Z, Yilmaz A, Ayhan M, Ersoy M, Guven DC, Erturk I, Durmus Y, Karacin P, Boran N, Ustun YE, Meydan M, Dogan M, Oksuzoğlu B, Ates O, Karaca M, Uncu D, Ergun Y, and Arik Z
- Subjects
- Humans, Female, Adult, Middle Aged, Aged, Bevacizumab adverse effects, Retrospective Studies, Ovarian Neoplasms pathology, Peritoneal Neoplasms drug therapy, Cystadenocarcinoma, Serous
- Abstract
Aim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded. Results: The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8). Conclusion: Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.
- Published
- 2024
- Full Text
- View/download PDF
40. Is adjuvant chemotherapy necessary for 2014 FIGO stage IC adult granulosa cell tumor?: Multicentric Turkish study.
- Author
-
Erdogan O, Kilic C, Cakir C, Kilic F, Oktar O, Ersak B, Sahin M, Tokalioglu A, Kocak O, Ozturk C, Gorgulu G, Gokkaya M, Selcuk I, Korkmaz V, Comert GK, Toptas T, Ureyen I, Ucar G, Taskin S, Tasci T, Uncu D, Narin MA, Boran N, Ozdal B, Tekin OM, Ustun Y, Sancı M, Ortac F, and Turan T
- Subjects
- Adult, Female, Humans, Neoplasm Staging, Chemotherapy, Adjuvant, Combined Modality Therapy, Retrospective Studies, Granulosa Cell Tumor drug therapy, Granulosa Cell Tumor pathology, Ovarian Neoplasms drug therapy
- Abstract
Aim: The aim of our study is to examine the clinical, surgical, and pathological factors of stage 1C adult granulosa cell tumor (AGCT) patients and to investigate the effects of adjuvant therapy on recurrence and survival rates in this patient group., Methods: Out of a total of 415 AGCT patients treated by 10 tertiary oncology centers participating in the study, 63 (15.2%) patients with 2014 FIGO stage IC constituted the study group. The FIGO 2014 system was used for staging. Patient group who received adjuvant chemotherapy was compared with patient group who did not receive adjuvant chemotherapy in terms of disease-free survival (DFS), and disease-specific survival., Results: The 5-year DFS of the study cohort was 89%, and the 10-year DFS was 85%. Those who received adjuvant chemotherapy and those who did not were similar in terms of clinical, surgical and pathological factors, except for peritoneal cytology. In the univariate analysis, none of the clinical, surgical or pathological factors were significant for DFS. Adjuvant chemotherapy and type of treatment protocol had no impact on DFS., Conclusion: Adjuvant chemotherapy was not associated with improved DFS and overall survival in stage IC AGCT. Multicentric and randomized controlled studies are needed for early stage AGCT in order to confirm these results and reach accurate conclusions., (© 2023 John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
41. Assessment of the differences in oncologic outcomes between patients with high-grade serous ovarian carcinoma and uterine serous carcinoma.
- Author
-
Kilic F, Ersak B, Cakir C, Yuksel D, Kilic C, Korkmaz V, Tokgozoglu N, Toptas T, Boran N, Kimyon Comert G, Ureyen I, Tasci T, Moraloglu Tekin O, Ustun Y, and Turan T
- Subjects
- Female, Humans, Retrospective Studies, Uterine Neoplasms pathology, Cystadenocarcinoma, Serous pathology, Carcinoma, Ovarian Neoplasms pathology
- Abstract
Aim: To evaluate whether the recurrence rates, recurrence patterns, and survival outcomes differed according to the primary site of the tumor in patients with high-grade serous ovarian carcinoma (HGSOC) and uterine serous carcinoma (USC)., Methods: The population of this multicenter retrospective study consisted of patients who had USC or HGSOC. Progression-free survival (PFS) and disease-specific survival (DSS) estimates were determined using the Kaplan-Meier method. Survival curves were compared using the log-rank test., Results: The study cohort consisted of 247 patients with HGSOC and 34 with USC. Recurrence developed in 118 (51.1%) in the HGSOC group and 14 (42.4%) in the USC group (p = 0.352). The median time to recurrence was 23.5 (range, 4-144) and 17 (range, 4-43) months in the HGSOC and USC groups, respectively (p = 0.055). The 3-year PFS was 52% in the HGSOC group and 47% in the USC group (p = 0.450). Additionally, 3-year DSS was 92% and 82% in the HGSOC and USC groups, respectively (p = 0.060)., Conclusions: HGSOC and USC are aggressive tumors with high recurrence and mortality rates in advanced stages. These two carcinomas, which are similar in molecular features and clinical management, may also have similar recurrence patterns, disease failure, and survival rates., (© 2023 Japan Society of Obstetrics and Gynecology.)
- Published
- 2024
- Full Text
- View/download PDF
42. Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: a Turkish multicentric study.
- Author
-
Unsal M, Kilic C, Cakir C, Kilic F, Ersak B, Karakas S, Tokgozoglu N, Varli B, Oktar O, Kimyon Comert G, Ozdemir IA, Boran N, Toptas T, Ureyen I, Korkmaz V, Taskin S, Moraloglu Tekin O, Ustun Y, Tasci T, Ortac F, and Turan T
- Subjects
- Humans, Female, Neoadjuvant Therapy, Neoplasm Staging, Prognosis, Retrospective Studies, Uterine Neoplasms drug therapy, Uterine Neoplasms surgery, Cystadenocarcinoma, Serous drug therapy, Cystadenocarcinoma, Serous surgery, Endometrial Neoplasms drug therapy, Endometrial Neoplasms pathology, Genital Neoplasms, Female
- Abstract
The aim of this study was to evaluate the prognostic factors for and determine the effect of neoadjuvant chemotherapy (NACT) on oncologic outcome in stage IVB pure serous endometrial carcinoma patients who received taxane and platinum. Forty-two patients with 2009 International Federation of Gynecology and Obstetrics (FIGO) stage IVB uterine serous carcinoma were enrolled from six gynecologic oncology centers and a study group was created. The study group had a 2-year disease-free survival (DFS) of 32% and 2-year disease-specific survival (DSS) of 73%. On univariate analysis; lymphadenectomy (not performed vs. performed), paraaortic lymph node metastasis (positive vs. negative) and number of metastatic lymph node count (≤5 vs. >5) were found to have statistical significance for DFS ( p < 0.001, p = 0.026 and p = 0.044, respectively). Adnexal metastasis (positive vs. negative) and type of cytoreductive surgery (maximal vs. optimal and suboptimal) had statistical significance for DSS ( p = 0.041 and p = 0.015, respectively). Receiving NACT did not affect DFS and DSS in stage IVB uterine serous carcinoma patients. As our sample size was small, precise conclusions could not be made for suggesting the use of NACT in advanced stage uterine serous carcinoma. For more accurate results, more randomized controlled studies are needed in this patient group.IMPACT STATEMENT What is already known on this subject? Endometrial carcinoma is the most common type of gynecologic tract malignancies and usually it is diagnosed at early stages. Although the favorable prognosis, uterine serous carcinoma (USC), one of the rarest subtypes, has a poorer prognosis when compared to other histological subtypes. USC has a propensity to spread beyond pelvis. Due to this aggressive behavior, surgical intervention could not be feasible in advanced stage disease. What do the results of this study add? Our study evaluated the prognostic factors that affect survival in advanced stage USC patients. Also we investigated that neoadjuvant chemotherapy (NACT) could improve oncologic outcomes. Performing lymphadenectomy, presence of paraaortic lymph node and adnexal metastasis, number of metastatic lymph nodes and type of cytoreductive surgery improved survival in advanced stage USC patients. However, NACT did not have a statistical significance as a predictor for disease-specific survival (DSS) and disease-free survival (DFS). What are the implications of these findings for clinical practice and/or further research? Maximal surgical effort should be performed in advanced stage USC according to our results. On the other hand, NACT had no impact on DSS and DFS rates. For this reason, we could not be able to suggest the routine use of NACT in advanced stage USC. But more randomized controlled trials are warranted for confirmation of our results.
- Published
- 2023
- Full Text
- View/download PDF
43. Clinicopathological features of atypical glandular cells, not otherwise specified, on cervicovaginal pap smears.
- Author
-
Aytekin O, Cakir C, Unsal M, Celik F, Tokalioglu AA, Kilic F, Ersak B, Codal B, Kahraman A, Gokkaya M, Ayhan S, Akar S, Cesur N, Erdogan F, Ozdal B, Oktar O, Koc S, Boran N, Comert GK, Ureyen I, Toptas T, Korkmaz V, Ustun Y, Tekin OM, Turkmen O, and Turan T
- Subjects
- Humans, Female, Papanicolaou Test, Vaginal Smears methods, Retrospective Studies, Cervix Uteri pathology, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms pathology, Precancerous Conditions pathology, Uterine Cervical Dysplasia pathology
- Abstract
Objective: The Papanicolaou (Pap) smear test is a standard screening test that detects cervical lesions and cancers. In this multicentric study, we performed a retrospective analysis of cytological results associated with atypical glandular cells, not otherwise specified (AGC-NOS)., Methods: We retrospectively reviewed Pap smear tests that resulted as AGC-NOS. A total of 254 women who underwent colposcopy due to a Pap smear result of AGC-NOS were included the study between 2003 and 2021. The ages, Pap smear results, HPV results if any, colposcopic biopsy results, endocervical and endometrial pathology results, and management of these patients were analysed., Results: Two hundred fifty-four patients with AGC-NOS Pap smear results were included in the study. A total of 70 (27.6%) patients had cervical and endometrial premalignant or malignant lesions. Malignancy was observed in 17 (6.7%) patients (endometrium, n = 11 [4.3%]; cervix, n = 6 [2.4%]). Isolated premalignant or malignant lesions of the cervix and endometrium were detected in 57 (22.4%) and 12 (4.7%) patients, respectively., Conclusions: Patients diagnosed with AGC-NOS should undergo a careful evaluation with all clinicopathological features. Because cancer of the cervix and endometrium is not rare in patients diagnosed with AGC-NOS, colposcopic examination with endocervical sampling should be a priority based on a cervicovaginal smear. Endometrial sampling is also required according to the patient's clinic, age, and examination characteristics., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
44. A multicentre evaluation and expert recommendations of use of the newly developed BioFire Joint Infection polymerase chain reaction panel.
- Author
-
Saeed K, Ahmad-Saeed N, Annett R, Barlow G, Barrett L, Boyd SE, Boran N, Davies P, Hughes H, Jones G, Leach L, Lynch M, Nayar D, Maloney RJ, Marsh M, Milburn O, Mitchell S, Moffat L, Moore LSP, Murphy ME, O'Shea SA, O'Sullivan F, Peach T, Petridou C, Reidy N, Selvaratnam M, Talbot B, Taylor V, Wearmouth D, and Aldridge C
- Subjects
- Child, Adult, Humans, Retrospective Studies, Polymerase Chain Reaction, Synovial Fluid microbiology, Arthritis, Infectious diagnosis, Arthritis, Infectious microbiology, Kingella kingae genetics
- Abstract
Septic arthritis is a serious condition with significant morbidity and mortality, routinely diagnosed using culture. The FDA has recently approved the rapid molecular BioFire® Joint Infection Panel (BJIP) for synovial fluid. We aimed to evaluate the BJIP compared to culture and its potential use in patient management. A multicentre retrospective evaluation of BJIP was conducted in the UK and Ireland. Positive percent agreement (PPA) and negative percent agreement (NPA) were calculated between the BJIP and routine culture. A multidisciplinary team (MDT) discussion addressing the optimal or potential case use of the assay practice was facilitated. Three hundred ninety-nine surplus synovial fluid samples (~ 70% from native joints) from eight centres were processed using BJIP in addition to routine culture. An increased yield of positive results was detected using BJIP compared to routine culture (98 vs 83), giving an overall PPA of 91.6% and overall NPA of 93% for the BJIP compared to culture results. The BJIP detected resistant markers and additional organisms that could influence antibiotic choices including Neisseria gonorrhoeae and Kingella kingae. The MDT agreed that the assay could be used, in addition to standard methods, in adult and children patients with specialist advice use based on local needs. Rapid results from BJIP were assessed as having potential clinical impact on patient management. Organisms not included in the panel may be clinically significant and may limit the value of this test for PJI., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
45. Post-recurrence survival analysis of patients with pulmonary recurrence from gynaecologic cancers: a multi-institutional analysis of 122 patients.
- Author
-
Ersak B, Akar S, Demirayak G, Tokalioğlu AA, Aytekin O, Çakir C, Yüksel D, Tokgözoğlu N, Karakaş S, Önder AB, Çelik F, Ayhan S, Ünsal M, Boran N, Kiliç F, Cömert GK, Üreyen I, Toptaş T, Korkmaz V, Özdemir İA, Taşçi T, Türkmen O, Moraloğlu Tekin Ö, Engin-Üstün Y, and Turan T
- Subjects
- Female, Humans, Retrospective Studies, Survival Analysis, Neoplasm Recurrence, Local, Genital Neoplasms, Female therapy, Ovarian Neoplasms pathology
- Abstract
In this retrospective study, patients with epithelial gynaecologic cancer with pulmonary recurrence (PR) were evaluated from five national gynaecologic oncology clinics. Patients with a diagnosis of primary endometrial, ovarian/fallopian tube/peritoneal, cervical or vaginal/vulvar tumours who developed an initial PR were included in the study A total of 122 patients were included in the study. The median follow-up time after recurrence was 7.5 (range, 1-84) months. The 2-year PRS was 48% in the main cohort. The risk of death was more than seven times higher in patients who did not receive salvage chemotherapy compared with those who did (hazard ratio: 7.6, 95% CI: 3.0-18.9; p < .001). When squamous cell carcinoma was compared with the other tumour types, the risk of death increased more than three times (hazard ratio: 3.7, 95% CI: 1.4-9.6; p = .007).IMPACT STATEMENT What is already known on this subject? Pulmonary recurrence (PR) from gynaecologic malignancies is rare and can cause major clinical problem. Therefore, defining the clinical and pathologic characteristics and recurrence patterns are essential. What the results of this study add? This study demonstrates non-squamous subtype and salvage chemotherapy at PR were associated with improved survival. What of these findings for clinical practice and/or further research? To the best of our knowledge, our study is the largest study to investigate the clinico-pathologic characteristics, recurrence patterns, treatment options, and post-recurrence survival (PRS) in patients with PR from epithelial gynaecologic cancers. Future research should examine the underlying causes of these findings.
- Published
- 2022
- Full Text
- View/download PDF
46. The effect of adjuvant radiotherapy on oncological outcomes in patients with early-stage cervical carcinoma with only intermediate-risk factors: a propensity score matching analysis.
- Author
-
Turkmen O, Kilic F, Tokalioglu AA, Cakir C, Yuksel D, Kilic C, Boran N, Kimyon Comert G, and Turan T
- Subjects
- Female, Humans, Treatment Outcome, Neoplasm Staging, Lymphatic Metastasis, Margins of Excision, Propensity Score, Radiotherapy, Adjuvant, Lymph Node Excision, Hysterectomy methods, Retrospective Studies, Carcinoma, Squamous Cell surgery, Uterine Cervical Neoplasms radiotherapy, Uterine Cervical Neoplasms surgery, Uterine Cervical Neoplasms pathology
- Abstract
We aimed to evaluate whether adjuvant radiotherapy had a survival benefit for patients with early-stage cervical carcinoma with intermediate-risk factors. This study included patients who underwent radical hysterectomy and lymphadenectomy according to Wertheim-Okabayashi for stage IB1-IIA2 cervical carcinoma. Each patient had at least one intermediate-risk factor including tumour diameter ≥4 cm, deep stromal invasion, and positive lymphovascular space invasion (LVSI). Patients with lymph node metastasis, parametrial invasion, and positive surgical margins according to the final paraffin section were excluded. In total, 183 patients were included. Seventy-three (39.9%) patients had one, 85 (46.4%) had two, and 25 (13.7%) had three intermediate risk factors. Sixty-seven (36.6%) patients received adjuvant radiotherapy. There was a statistically significant difference in terms of stage, LVSI, and endometrial/uterine invasion between the groups that did and did not receive adjuvant radiotherapy ( p = .024, p = .018, and p = .001, respectively). These two groups were homogenised by performing propensity score matching (PSM) analysis. In the new matched cohort ( n = 134), 5-year disease-free survival (DFS) was 89.5% in the group that received adjuvant radiotherapy and 82% in the group that did not (HR: 0.484, 95% CI: [0.171-1.369]; p = .171). Also, receiving adjuvant radiotherapy was not associated with an improvement in oncologic outcomes in patients with one, two, or more intermediate risk factors. In univariate analysis, none of the risk factors was associated with DFS. In conclusion, adjuvant radiotherapy had no favourable effect on survival outcomes in patients with early-stage cervical carcinoma with only intermediate risk factors.IMPACT STATEMENT What is already known on this subject? Radiotherapy after radical hysterectomy in cervical carcinoma is accepted as the standard of care when high-risk factors - positive surgical margins, lymph node metastasis, and parametrial involvement - are found in the surgical specimen. However, the necessity of adjuvant radiotherapy in patients with intermediate-risk factors - deep stromal invasion, positive LVSI, tumour diameter ≥4 cm - is controversial. What do the results of this study add? We compared patients who received adjuvant radiotherapy and those who did not. No significant difference was found between the two groups in terms of oncologic outcomes. There was no difference between the two groups in terms of pelvic and extrapelvic recurrence rates. The number of positive intermediate-risk factors did not affect survival. Moreover, age, tumour type, stage, number of removed lymph nodes, grade, bilateral salpingo-oophorectomy, and endometrial/uterine invasion were not associated with DFS among patients with stage IB-IIA cervical carcinoma with only intermediate-risk factors. What are the implications of these findings for clinical practice and/or further research? Debate remains over the prognostic factors and the adjuvant treatment options in patients with early-stage cervical carcinoma who possess intermediate-risk factors. Adjuvant radiotherapy can be ignored if initial adequate surgery has been performed in this patient group.
- Published
- 2022
- Full Text
- View/download PDF
47. Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
- Author
-
Bostancı Eİ, Durmuş Y, Çöteli ASD, Kayakçıoğlu F, and Boran N
- Subjects
- Female, Humans, Conservative Treatment, Carcinoma, Endometrioid, Endometrial Hyperplasia
- Published
- 2022
- Full Text
- View/download PDF
48. Comparison of weekly methotrexate regimen versus methotrexate folinic acid 8-day regimen for treatment of low-risk gestational trophoblastic neoplasia.
- Author
-
Korkmaz V, Sunar V, Akar S, Alinca CM, Arik Z, Boran N, Ozdal B, and Ustun YE
- Subjects
- Adult, Female, Humans, Leucovorin adverse effects, Methotrexate, Middle Aged, Pregnancy, Retrospective Studies, Gestational Trophoblastic Disease chemically induced, Gestational Trophoblastic Disease drug therapy, Gestational Trophoblastic Disease pathology, Lung Neoplasms drug therapy
- Abstract
Aim: We aimed to compare weekly methotrexate (MTX) regimen and methotrexate-folinic acid (MTX-FA) 8-day regimen in the first line treatment of low-risk gestational trophoblastic neoplasia (GTN)., Methods: The study included 73 patients with low-risk GTN according to FIGO risk score (FIGO risk score < 7). All patients received either weekly MTX (30-50 mg/m
2 intramuscular weekly) or MTX-FA 8-day (MTX 1 mg/kg IV on day 1, 3, 5, and 7, FA 15 mg orally on day 2, 4, 6, and 8 given 24 h after each MTX dose, every 14 days) regimens in the first-line treatment of low-risk GTN. The baseline clinicopathological characteristics and treatment outcomes were analyzed retrospectively., Results: The median age of all patients was 29 (18-51) years, and the median FIGO risk score was 3 (1-6). Of the patients recruited, 53 received MTX-FA 8-day, and 20 had MTX weekly regimens. There was a significant difference between the two groups with respect to FIGO risk scores (3 [1-6] vs. 2 [1-5], p = 0.023, MTX-FA 8-day vs. MTX weekly, respectively). The complete response rate was significantly higher in MTX-FA 8-day group compared to MTX weekly group (83% [44/53] vs. 60% [12/20] p = 0.038). In univariate and multivariate regression analyses, only presence of lung metastasis was found to be an independent risk factor for treatment resistance (OR: 3.959, 95% CI 1.105-14.179, p = 0.035)., Conclusion: MTX-FA 8-day regimen is more effective than weekly MTX regimen in the first line treatment of low-risk GTN including patients even with higher FIGO risk scores. Treatment resistance may develop especially in patients with lung metastasis., (© 2021 John Wiley & Sons Australia, Ltd.)- Published
- 2022
- Full Text
- View/download PDF
49. Brenner tumors of the ovary: clinical features and outcomes in a single-center cohort
- Author
-
Yüksel D, Kılıç C, Çakır C, Kimyon Cömert G, Turan T, Ünlübilgin E, Boran N, Kayıkçıoğlu F, and Koç S
- Abstract
Objective: The purpose of the present study was to evaluate the clinical and pathological features and oncological outcomes of Brenner tumors (BT)., Material and Methods: Evaluation was performed on the data of 46 patients with BTs retrieved from the oncology clinic database and pathology reports between 2005 and 2020., Results: The median (range) age of the patients was 52 (22-75) years. Median (range) tumor size was 52.5 (5.0-300) mm. The tumor was benign in 37 (80.4%), borderline in one (2.2%), and malignant in the remaining eight (17.4%). Ten (21.7%) of the tumors were detected incidentally. Mixed tumor, BT plus another ovarian pathology, was found in 13 (28.2%). Recurrence developed in 2/8 (25%) with malignant BT (MBT). The stage of these patients was 3C, and both received chemotherapy after surgery., Conclusion: BTs are rare and generally detected incidentally. MBTs are treated in the same way as epithelial tumors. Due to the rarity of these tumors, lymphadenectomy and optimal chemotherapy regimens are controversial issues.
- Published
- 2022
- Full Text
- View/download PDF
50. Survival outcomes of women with grade 3 endometrioid endometrial cancer: the impact of adjuvant treatment strategies.
- Author
-
Gungorduk K, Muallem J, Aşıcıoğlu O, Gülseren V, Güleç ÜK, Meydanlı MM, Sehouli J, Özdemir A, Şahin H, Khatib G, Miranda A, Boran N, Şenol T, Yıldırım N, Turan T, Oge T, Taşkın S, Vardar MA, Ayhan A, and Muallem MZ
- Subjects
- Disease-Free Survival, Female, Humans, Lymph Node Excision, Neoplasm Staging, Prognosis, Retrospective Studies, Carcinoma, Endometrioid surgery, Endometrial Neoplasms surgery
- Abstract
Aim: This multicenter investigation was performed to evaluate the adjuvant treatment options, prognostic factors, and patterns of recurrence in patients with grade 3 endometrioid endometrial cancer (G3-EEC)., Materials and Methods: The medical reports of patients undergoing at least total hysterectomy and salpingo-oophorectomy for G3-EEC between 1996 and 2018 at 11 gynecological oncology centers were analyzed. Optimal surgery was defined as removal of all disease except for residual nodules with a maximum diameter ≤ 1 cm, as determined at completion of the primary operation. Adequate systematic lymphadenectomy was defined as the removal of at least 15 pelvic and at least 5 paraaortic LNs., Results: The study population consists of 465 women with G3-EEC. The 5-year disease-free survival (DFS) and overall survival (OS) rates of the entire cohort are 50.3% and 57.6%, respectively. Adequate systematic lymphadenectomy was achieved in 429 (92.2%) patients. Optimal surgery was achieved in 135 (75.0%) patients in advanced stage. Inadequate lymphadenectomy (DFS; HR 3.4, 95% CI 3.0-5.6; P = 0.016-OS; HR 3.2, 95% CI 1.6-6.5; P = 0.019) was independent prognostic factors for 5-year DFS and OS., Conclusion: Inadequate lymphadenectomy and LVSI were independent prognostic factors for worse DFS and OS in women with stage I-II G3-EEC. Adequate lymphadenectomy and optimal surgery were independent prognostic factors for better DFS and OS in women with stage III-IV G3-EEC., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.